Pulished Date October, 2018
ID: 786
Share on
Share on

North America Kidney Cancer Diagnostics And Therapeutics Market By Type (Transitional Cell Cancer, Renal Cell Carcinoma, Renal Sarcoma, Others), By Tests (Biopsy, CT Scan, Cystoscopy, Intravenous Pyelogram, Kidney Ultrasound), And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018-2023)

Pulished: October, 2018
ID: 786
Pages: 137

The North America Kidney Cancer Diagnostics and Therapeutics Market was worth $1.25 billion in 2018 and estimated to be growing at a CAGR of 5.51%, to reach $1.63 billion by 2023. Though there has been extensive progress in science and technology to tackle cancer, it continues to threaten lives across the world.

Kidney cancer is one of the recurrent urologic tumours accounting for around 3% of all the human cancers. The occurrence rate of renal cell carcinoma has increased progressively in the recent decades.

The growth of the North America Kidney Cancer Diagnostics and Therapeutics Market is mainly driven by factors such as rising aging population, Changes in lifestyle such as increased intake of alcohol and disproportionate smoking, and government policies to provide better care for kidney Cancer. However, high treatment cost is one of the main factor hampering the growth of the market in this region.

The North America Kidney Cancer Diagnostics and Therapeutics market is segmented based on Type and Tests. The market for Kidney Cancer Diagnostics and Therapeutics, on the basis of Type is segmented into Transitional Cell Cancer, Renal cell carcinoma, Renal sarcoma, and Others. On the basis of Tests, the Kidney Cancer Diagnostics and Therapeutics market is segmented into Biopsy, CT Scan, Cystoscopy, Intravenous pyelogram, Kidney Ultrasound. Biopsy and CT Scan lead the tests segment in the Kidney Cancer Diagnostics and Therapeutics market accounting for more than 50% of the market.

The North America Kidney Cancer Diagnostics and Therapeutics market has been geographically segmented into segmented into US and Canada. The North America market is advanced and is focused on inventing cost-effective techniques. Companies are dedicated to research, sourcing, and quality, factors that are vital to the success of the industry.

The major companies dominating the Kidney Cancer Diagnostics and Therapeutics market in this region are GlaxoSmithKline, Bayer, Pfizer, Sanofi S.A, Hoffmann La Roche, Novartis, Abbott Laboratories.

1.Introduction                              

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By Type                     

                             5.1.1 Transitional Cell Cancer    

                             5.1.2 Renal cell carcinoma         

                             5.1.3 Renal sarcoma     

                             5.1.4 Other Cancers      

              5.2 By Tests                     

                             5.2.1 Biopsy      

                             5.2.2 CT Scan    

                             5.2.3 Cystoscopy            

                             5.2.4 Intravenous pyelogram    

                             5.2.5 Kidney Ultrasound             

6. Geographical Analysis                                         

              6.1 Introduction                           

              6.2 United States                          

              6.3 Canada                      

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8.Strategic Analysis                                    

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9.Market Leaders' Analysis                                     

              9.1 GlaxoSmithKline                    

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 Bayer                         

              9.3 Pfizer                         

              9.4 Sanofi S.A                 

              9.5 Hoffmann La Roche              

              9.6 Novartis                    

              9.7 Abbott Laboratories                            

10.Competitive Landscape                                      

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11.Expert Opinions                                    

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Kidney Cancer Diagnostics and Therapeutics Market By Region, From 2018-2023 (USD Billion)
  2. North America Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2018-2023 (USD Billion)
  3. North America Transitional Cell Cancer Market By Region, From 2018-2023 (USD Billion)
  4. North America Renal cell carcinoma Market By Region, From 2018-2023 (USD Billion)
  5. North America Renal sarcoma Market By Region, From 2018-2023 (USD Billion)
  6. North America Other Kidney Cancers Market By Region, From 2018-2023 (USD Billion)
  7. North America Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2018-2023 (USD Billion)
  8. North America Biopsy Market By Region, From 2018-2023 (USD Billion)
  9. North America CT Scan Market By Region, From 2018-2023 (USD Billion)
  10. North America Cystoscopy Market By Region, From 2018-2023 (USD Billion)
  11. North America Intravenous pyelogram Market By Region, From 2018-2023 (USD Billion)
  12. North America Kidney Ultrasound Market By Region, From 2018-2023 (USD Billion)
  13. United States Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2018-2023 (USD Billion)
  14. United States Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2018-2023 (USD Billion)
  15. Canada Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2018-2023 (USD Billion)
  16. Canada Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2018-2023 (USD Billion)

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients